Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: Indication of close relation between myocardial iron content and chelatable iron pool

Blood

Volumn 101, Issue 11, 2003, Pages 4632-4639

  Jensen, Peter D ^a   Jensen, Finn T ^b   Christensen, Thorkil ^b   Eiskjær, Hans ^b   Baandrup, Ulrik ^b   Nielsen, Johan L ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; IRON; IRON CHELATING AGENT; FERRITIN;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; HEART MUSCLE; HEMATOLOGIC MALIGNANCY; HEMOCHROMATOSIS; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REPRODUCIBILITY; STATISTICAL SIGNIFICANCE; URINARY EXCRETION; ANEMIA; BLOOD; CASE CONTROL STUDY; CHELATION THERAPY; CHEMISTRY; FOLLOW UP; HEART DISEASE; MIDDLE AGED; URINE;

ADULT; AGED; ANEMIA; CASE-CONTROL STUDIES; CHELATION THERAPY; DEFEROXAMINE; FERRITINS; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MYOCARDIUM; REPRODUCIBILITY OF RESULTS;

EID: 0038481233     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2754     Document Type: Article

References (51)

1. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051-2052.
2. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med. 1971;51:209-221.
3. Fitchett DH, Coltart DJ, Littler WA, et al. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res. 1980;14:719-724.
4. Olson LJ, Edwards WD, McCall JT, Ilstrup DM, Gersh BJ. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol. 1987;10:1239-1243.
5. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med. 1982;307:1671-1675.
6. Fischer R. Liver iron susceptometry. In: Andra W, Novak H, eds. Magnetism in Medicine: A Handbook. Berlin, Germany: Wiley-VCH; 1998:286-301.
7. Brasch RC, Wesbey GE, Gooding CA, Koerper MA. Magnetic resonance imaging of transfusional hemosiderosis complicating thalassemia major. Radiology. 1984;150:767-771.
8. Stark DD, Moseley ME, Bacon BR, et al. Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology. 1985;154:137-142.
9. Kaltwasser JP, Gottschalk R, Schalk KP, Hartl W. Non-invasive quantitation of liver iron-overload by magnetic resonance imaging. Br J Haematol. 1990;74:360-363.
10. Bonkovsky HL, Slaker DP, Bills EB, Wolf DC. Usefulness and limitations of laboratory and hepatic imaging studies in iron-storage disease. Gastroenterology. 1990;99:1079-1091.
11. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. Br J Haematol. 1994;87:171-184.
12. Angelucci E, Giovagnoni A, Valeri G, et al. Limitations of magnetic resonance imaging in measurement of hepatic iron. Blood. 1997;90:4736-4742.
13. Ernst O, Sergent G, Bonvarlet P, Canva-Delcambre V, Paris JC, L'Hermine C. Hepatic iron overload: diagnosis and quantification with MR imaging. AJR Am J Roentgenol. 1997;168:1205-1208.
14. Johnston DL, Rice L, Vick GW 3rd, Hedrick TD, Rokey R. Assessment of tissue iron overload by nuclear magnetic resonance imaging. Am J Med. 1989;87:40-47.
15. Mavrogeni SI, Gotsis ED, Markussis V, et al. T2 relaxation time study of iron overload in b-thalassemia. Magma. 1998;6:7-12.
16. Papanikolaou N, Ghiatas A, Kattamis A, Ladis C, Kritikos N, Kattamis C. Non-invasive myocardial iron assessment in thalassaemic patients. T2 relaxometry and magnetization transfer ratio measurements. Acta Radiol. 2000;41:348-351.
17. Jensen PD, Jensen FT, Christensen T, Heickendorff L, Jensen LG, Ellegaard J. Indirect evidence for the potential ability of magnetic resonance imaging to evaluate the myocardial iron content in patients with transfusional iron overload. Magma. 2001;12:153-166.
18. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-2179.
19. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients. Br J Haematol. 1995;89:880-889.
20. Jensen PD, Olsen N, Bagger JP, Jensen FT, Christensen T, Ellegaard J. Cardiac function during iron chelation therapy in adult non-thalassaemic patients with transfusional iron overload. Eur J Haematol. 1997;59:221-230.
21. Pippard MJ. Desferrioxamine-induced iron excretion in humans. Baillieres Clin Haematol. 1989;2:323-343.
22. Zettner A, Mansbach L. Application of atomic absorption spectrophotometry in the determination of iron in urine. Am J Clin Pathol. 1965;44:517-519.
23. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
24. Hackman R, Sher GD, Milone SD, et al. The imaging of cardiac iron in transfusion dependent patients: still an uncertain science [abstract]. Blood. 1993;82:96a.
25. Olivieri NF, Belluzzo M, Muraca M, et al. Evidence of hepatic, cardiac and pituitary iron stores in patients with thalassaemia major during longterm therapy with orally active iron chelating agent L1 [abstract]. Blood. 1994;84:109a.
26. Olivieri NF, Koren G, Matsui D, et ak. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 1992;79:2741-2748.
27. Chan PC, Liu P, Cronin C, Heathcote J, Uldall R. The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy. Am J Kidney Dis. 1992;19:484-489.
28. Olson LJ, Edwards WD, Holmes DR Jr, Miller FA Jr, Nordstrom LA, Baldus WP. Endomyocardial biopsy in hemochromatosis: clinicopathologic correlates in six cases. J Am Coll Cardiol. 1989;13:116-120.
29. Gandon Y, Guyader D, Heautot JF, et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology. 1994;193:533-538.
30. Bonkovsky HL, Rubin RB, Cable EE, Davidoff A, Rijcken TH, Stark DD. Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques. Radiology. 1999;212:227-234.
31. Stark DD. Hepatic iron overload: paramagnetic pathology. Radiology. 1991;179:333-335.
32. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effect of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360:516-520.
33. Mortensen SA, Baandrup U. Endomyocardial biopsy with a modified bioptome introducer sheath: focus on diagnostic yield and prevention of complications. Cathet Cardiovasc Diagn. 1987;13:194-203.
34. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101:91-96.
35. Hershko C, Rachmilewitz EA. Mechanism of desferrioxamine-induced iron excretion in thalassaemia. Br J Haematol. 1979;42:125-132.
36. Hershko C, Konijn AM, Link G. Iron chelators for thalassaemia. Br J Haematol. 1998;101:399-406.
37. Gutteridge JM, Rowley DA, Griffiths E, Halliwell B. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci (Colch). 1985;68:463-467.
38. Parkes JG, Hussain RA, Olivieri N, Tempelton DM. Effect of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. J Lab Clin Med. 1993;122:36-47.
39. Link G, Pinson A, Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med. 1985;106:147-153.
40. Umbreit JN CM, Moore EG, Latour LF. Iron absorption and cellular transport. The mobilferrin/paraferritin paradigm. Semin Hematol. 1998;35:13-25.
41. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood. 1996;88:705-713.
42. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk betathalassemia. Blood. 2000;95:1229-1236.
43. Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol. 2002;15:329-368.
44. Jacobs A. Low molecular weight intracellular iron transport compounds. Blood. 1977;50:433-439.
45. Breuer W, Epsztejn S, Zl C. Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Lett. 1997;382:304-308.
46. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574-578.
47. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971-977.
48. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-573.
49. Pippard MJ, Callender ST, Finch CA. Ferrioxamine excretion in iron-loaded man. Blood. 1982;60:288-294.
50. Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J Clin Pathol. 1990;43:638-640.
51. Barosi G, Arbustini E, Gavazzi A, Grasso M, Pucci A. Myocardial iron grading by endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients. Eur J Haematol. 1989;42:382-388.